Pharmacology

bisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, traumabisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, trauma

bisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, traumabisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, trauma

bisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, traumabisphosphonate therapy, Southampton University Hospital, fractures, prodromal pain, trauma

first trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant usefirst trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant use

first trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant usefirst trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant use

first trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant usefirst trimester, pregnancy, over-the-counter medicines, OTC, Boston University, Harvard School of Public Health, Centers for Disease Control and Prevention (CDC), National Birth Defects Prevention Study, NBDPS, Slone Epidemiology Center Birth Defects Study, BDS, antidepressant use

metastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registrymetastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registry

metastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registrymetastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registry

metastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registrymetastatic pancreatic cancer, MPC, chemotherapy, Creighton University Medical Center, University of Nebraska Medical Center, VA Nebraska-Western Iowa Health Care System, Veterans Affairs Central Cancer Registry

breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17

breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17

breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17breast cancer, HER2-positive, trastuzumab, Herceptin, genetic screening test, Inform Dual ISH, HER2 gene, tumor tissue, chromosome 17

serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders

serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders

serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders serotonin reuptake inhibitors, SSRIs, depression, pregnancy, congenital anomalies, septal heart defects, anencephaly, limb reduction defects, Helsinki University Central Hospital and HUSLAB, National Institute for Health and Welfare, Nordic School of Public Health, fetal anomalies, paroxetine, citalopram, fetal alcohol spectrum disorders

cardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safetycardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safety

cardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safetycardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safety

cardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safetycardiac disease, tiotropium mist inhalers, chronic obstructive pulmonary disease, COPD, Johns Hopkins University School of Medicine, University of East Anglia, University of Arizona, Wake Forest University School of Medicine, dose-response relationship, pulmonary disease, safety

rheumatoid arthritis, RA, psoriasis, diabetes, insulin resistance, disease-modifying antirheumatic drugs, DMARDs, tumor necrosis factor inhibitors, TNF, hydroxychloroquine, diabetes mellitus, DM, Brigham and Women's Hospitalrheumatoid arthritis, RA, psoriasis, diabetes, insulin resistance, disease-modifying antirheumatic drugs, DMARDs, tumor necrosis factor inhibitors, TNF, hydroxychloroquine, diabetes mellitus, DM, Brigham and Women's Hospital

rheumatoid arthritis, RA, psoriasis, diabetes, insulin resistance, disease-modifying antirheumatic drugs, DMARDs, tumor necrosis factor inhibitors, TNF, hydroxychloroquine, diabetes mellitus, DM, Brigham and Women's Hospitalrheumatoid arthritis, RA, psoriasis, diabetes, insulin resistance, disease-modifying antirheumatic drugs, DMARDs, tumor necrosis factor inhibitors, TNF, hydroxychloroquine, diabetes mellitus, DM, Brigham and Women's Hospital

rheumatoid arthritis, RA, psoriasis, diabetes, insulin resistance, disease-modifying antirheumatic drugs, DMARDs, tumor necrosis factor inhibitors, TNF, hydroxychloroquine, diabetes mellitus, DM, Brigham and Women's Hospitalrheumatoid arthritis, RA, psoriasis, diabetes, insulin resistance, disease-modifying antirheumatic drugs, DMARDs, tumor necrosis factor inhibitors, TNF, hydroxychloroquine, diabetes mellitus, DM, Brigham and Women's Hospital

levothyroxtine, hypothyroidism, University of Toronto, seizure, trauma, cancer, fracture, cardia arrhythmia, dementia, serotonin reuptake inhibitors, osteoporosislevothyroxtine, hypothyroidism, University of Toronto, seizure, trauma, cancer, fracture, cardia arrhythmia, dementia, serotonin reuptake inhibitors, osteoporosis

levothyroxtine, hypothyroidism, University of Toronto, seizure, trauma, cancer, fracture, cardia arrhythmia, dementia, serotonin reuptake inhibitors, osteoporosislevothyroxtine, hypothyroidism, University of Toronto, seizure, trauma, cancer, fracture, cardia arrhythmia, dementia, serotonin reuptake inhibitors, osteoporosis

levothyroxtine, hypothyroidism, University of Toronto, seizure, trauma, cancer, fracture, cardia arrhythmia, dementia, serotonin reuptake inhibitors, osteoporosislevothyroxtine, hypothyroidism, University of Toronto, seizure, trauma, cancer, fracture, cardia arrhythmia, dementia, serotonin reuptake inhibitors, osteoporosis

essential amino acids, EAAs, geriatric patients, Istituto Geriatrico Piero Redaelli, maltodextrine, nonreactant proteins, blood urea nitrogen, serum creatine levels, C-reactive protein, CRP, hemoglobin, Hbessential amino acids, EAAs, geriatric patients, Istituto Geriatrico Piero Redaelli, maltodextrine, nonreactant proteins, blood urea nitrogen, serum creatine levels, C-reactive protein, CRP, hemoglobin, Hb

essential amino acids, EAAs, geriatric patients, Istituto Geriatrico Piero Redaelli, maltodextrine, nonreactant proteins, blood urea nitrogen, serum creatine levels, C-reactive protein, CRP, hemoglobin, Hbessential amino acids, EAAs, geriatric patients, Istituto Geriatrico Piero Redaelli, maltodextrine, nonreactant proteins, blood urea nitrogen, serum creatine levels, C-reactive protein, CRP, hemoglobin, Hb

essential amino acids, EAAs, geriatric patients, Istituto Geriatrico Piero Redaelli, maltodextrine, nonreactant proteins, blood urea nitrogen, serum creatine levels, C-reactive protein, CRP, hemoglobin, Hbessential amino acids, EAAs, geriatric patients, Istituto Geriatrico Piero Redaelli, maltodextrine, nonreactant proteins, blood urea nitrogen, serum creatine levels, C-reactive protein, CRP, hemoglobin, Hb

antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin

antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin

antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin antihypoglycemic agent, metformin-plus-sulfonylurea therapy, Universidade Federal do Rio Grande do Sul, Federal University of Rio Grande do Sul, acarbose, thiazolidinediones, glucagon-like peptide-1 agonists, GLP-1, dipeptidyl peptidase-4 inhibitors, DPP-4, insulin